Oncocytic lipoadenoma of the parotid gland: a case report and a review of the literature.

Oncocytic lipoadenomas are a rare sub-category of fat-containing tumors of the salivary glands. These tumors are characterized by their oncocyte-predominant epithelial component admixed with mature adipocytes. This condition has been rarely reported to affect the parotid and the submandibular glands.

Multinodular goiter with a retropharyngeal extension: A report of two cases and literature review.

Multinodular goiter (MNG) is a chronic benign nodular enlargement of the thyroid gland. It presents as an anterior painless neck mass, potentially progressing to exert pressure on the trachea and esophagus and giving rise to compressive symptoms. MNG is a common thyroid gland disorder; however, retropharyngeal goiter is considered rare with few reported cases.

Pre-treatment metabolic tumor volume predicts tumor metastasis and progression in high-grade salivary gland carcinoma.

Purpose: High-grade salivary gland carcinoma (SGC) shows a high rate of metastasis and post-treatment recurrence, resulting in poor patient survival. Therefore, we evaluated the utility of pre-treatment F-FDG PET/CT parameters in predicting metastasis, tumor progression, and survival of high-grade SGC patients.

Methods: This observational study included 75 patients with previously untreated high-grade SGC who underwent pre-treatment F-FDG PET/CT scanning and subsequent treatment.

Prognostic value of F-FDG PET/CT parameters in patients who undergo salvage treatments for recurrent squamous cell carcinoma of the larynx and hypopharynx.

Background: Recurrent laryngeal/hypopharyngeal squamous cell carcinoma (LHSCC) is commonly associated with poor survival outcomes. We evaluated the prognostic role of F-fluorodeoxyglucose positron emission tomography/computed tomography ( F-FDG PET/CT) parameters quantitatively measured in patients who underwent salvage treatments for recurrent LHSCC.

Methods: This study involved 100 consecutive LHSCC patients who underwent F-FDG PET/CT for recurrent staging and subsequent salvage treatments.